|Bid||8.19 x 1100|
|Ask||8.40 x 1100|
|Day's range||7.95 - 10.08|
|52-week range||7.34 - 58.37|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||29 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.00|
Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -122.22% and -41.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the first quarter ended March 31, 2021.
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.